Piper Sandler analyst Biren Amin maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating, and adjusts the target price from $200 to $182.
According to TipRanks data, the analyst has a success rate of 42.8% and a total average return of 0.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following Sarepta's announcement of a licensing agreement with Arrowhead, an analyst noted the agreement, which includes four clinical and three preclinical programs, accompanied by an upfront payment of $500M and a $325M equity investment, could substantially enhance the company's pipeline. This development potentially offers additional revenue streams beyond its DMD franchise over the long term. The arrangement is viewed positively as it could address concerns regarding Sarepta's need for diversification beyond singular gene therapy approaches.
The partnership with Arrowhead provides Sarepta with platform diversification and a long-term investment in strategies for rare diseases across various therapeutic areas including muscle, central nervous system, and pulmonary conditions. This strategy aligns well with Sarepta's established expertise in rare genetic medicine. Further positive sentiment is derived from the firm's share buyback program, indicating a strong confidence in impending revenue prospects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派傑投資分析師Biren Amin維持$Sarepta Therapeutics (SRPT.US)$買入評級，並將目標價從200美元下調至182美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.8%，總平均回報率為0.8%。
此外，綜合報道，$Sarepta Therapeutics (SRPT.US)$近期主要分析師觀點如下：
在Sarepta宣佈與Arrowhead簽署許可協議後，一位分析師指出，該協議包括四個臨床和三個臨床前項目，附帶50000萬美元的預付款和32500萬美元的股權投資，這可能大大增強公司的產品線。此發展可能在長期內爲其DMD業務提供額外的營業收入來源。該安排受到積極評價，因爲它可以解決關於Sarepta在單一基因治療方法之外需要多元化的擔憂。
與Arrowhead的合作爲Sarepta提供了平台多元化和對罕見疾病策略的長期投資，涉及肌肉、中樞神經系統和肺部病症等多個治療領域。該策略與Sarepta在罕見基因醫學方面的既有專業性非常契合。進一步的積極情緒源自於該公司的股票回購計劃，表明對即將到來的營業收入前景充滿信心。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
